Science Explorer Back to mapMap
Discussion
Researcher · Eutropics Pharmaceuticals (United States) · United States

Ryan J. Lena

Ryan J. Lena publishes mostly in Molecular Biology, Hematology and Oncology, on topics such as RNA Interference and Gene Delivery, Acute Myeloid Leukemia Research and Cell death mechanisms and regulation.

ORCID 0000-0003-1282-9492 OpenAlex
World rank
#5,299,494
of 7,710,434 ranked researchers
Rank in United States
#1,352,182
of 1,627,098
Works
49
Citations
369
Citations per work
7.5
h-index
6
i10-index 6Top 94% in Molecular Biology
Ryan J. Lena

What does Ryan J. Lena research?

Ryan J. Lena's work is mostly in Biochemistry, Genetics and Molecular Biology (42%), Medicine (24%), Chemistry (12%).

Life Sciences: 21 works · 42.4% of their workBiochemistry, Genetics and Molecular Biology: 21 works · 42.4% of their workMolecular Biology: 21 works · 42.4% of their workHealth Sciences: 12 works · 23.8% of their workMedicine: 12 works · 23.8% of their workHematology: 6 works · 11.9% of their workOncology: 3 works · 6.8% of their workGenetics: 2 works · 5.1% of their workEverything else: 11 works · 21.9% of their workPhysical Sciences: 6 works · 11.9% of their workChemistry: 6 works · 11.9% of their workOrganic Chemistry: 3 works · 6.8% of their workSpectroscopy: 2 works · 5.1% of their workTHEIR WORKRyan J. Lena49works
Life Sciences42%Physical Sciences12%Health Sciences24%

Their six largest subfields, inside their fields and domains; the grey slice is everything else they publish. The interactive view splits every one of their works down to single topics.

The fields and subfields, with their numbers
    1. Biochemistry, Genetics and Molecular Biology2142.4%
    1. Medicine1223.8%
  3. Everything else1121.9%
    1. Chemistry611.9%
  1. 1Molecular Biology42% of their works
  2. 2Hematology12% of their works
  3. 3Oncology7% of their works
  4. 4Organic Chemistry7% of their works
  5. 5Spectroscopy5% of their works
  6. 6Genetics5% of their works

Research topics

Which keywords describe Ryan J. Lena's research?

The keywords of their largest research topics: Cancer Therapy, Prognostic Factors, Apoptosis, Acute Myeloid Leukemia, AML, RNA Interference, siRNA Delivery and Bcl-2 Family.

Size is their works in the topics tagged with each word, from their 8 largest topics. Each links to the topic it comes from most. The words come from the keyword list OpenAlex gives each topic, not from the text of the papers, so a word can appear that none of the papers uses.

All 19 words, with their numbers
  1. Cancer Therapy93 topics
  2. Prognostic Factors82 topics
  3. Apoptosis72 topics
  4. AML51 topic
  5. Acute Myeloid Leukemia51 topic
  6. RNA Interference51 topic
  7. siRNA Delivery51 topic
  8. BET Bromodomains41 topic
  9. Bcl-2 Family41 topic
  10. Cell Death41 topic
  11. PROTACs41 topic
  12. Cell Cycle31 topic
  13. Chronic Lymphocytic Leukemia31 topic
  14. DNA nanotechnology31 topic
  15. Genomic Aberrations31 topic
  16. Self-Assembly31 topic
  17. p5331 topic
  18. HDAC Inhibitors21 topic
  19. Histone Deacetylases21 topic

Where does Ryan J. Lena work?

Ryan J. Lena's main affiliation in the publication record is Eutropics Pharmaceuticals (United States), United States.

How many publications and citations does Ryan J. Lena have?

OpenAlex counts 49 works and 369 citations for Ryan J. Lena, an h-index of 6, ranking #5,299,494 of 7,710,434 researchers worldwide on the quality score.

Ranked on field-normalised citation excellence (50%), output (30%) and citations (20%). Counts come from OpenAlex author records, which occasionally merge different people who share a name or split one person into several.

Papers, co-authors, who cited this work and researchers on the nearest topics have tabs of their own, above. Is this your page? Claim it with your ORCID iD, or request a correction or removal.

Discussion

Ask a question or share a note about Ryan J. Lena. Keep it to the research: no personal attacks, advertising or links. Any reader can report a post, which collapses it for everyone until it is opened.